Skip to main content

Building a National Framework for the Establishment of Regulatory Science for Drug Development Workshop Summary (2011) / Chapter Skim
Currently Skimming:

Appendix A: Agenda
Pages 57-60

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 57...
... Appendix A Agenda Building a National Framework for the Establishment of Regulatory Science for Drug Development February 26, 2010 National Academy of Sciences Building Lecture Room 2100 C Street NW Washington, DC 8:00–8:15 OPENINg REMARKS Drug Forum Co-Chairs: gail Cassell, Eli Lilly and Company Jeffrey Drazen, New England Journal of Medicine 8:15–8:45 REguLATORy SCIENCE: OvERvIEW Moderator: Jeffrey Drazen, New England Journal of Medicine garret Fitzgerald, Institute for the Translational Medicine and Therapeutics, University of Pennsylvania 8:45–9:15 KEyNOTE SPEAKER Congresswoman Rosa DeLauro (D-CT) 9:15–10:00 FDA INITIATIvES ON REguLATORy SCIENCE Margaret Hamburg, FDA Commissioner 10:00–10:15 Break 5
Read the entire page →
From page 58...
... Moderator: Barbara Alving, National Center for Research Resources, NIH Translational Approaches to Understand and Predict Rare Adverse Reactions to Drugs Paul Watkins, Hamner–University of North Carolina Institute for Drug Safety Sciences A Role for Regulatory Science in Emerging Technologies: Genomics Allen Roses, Deane Drug Discovery Institute, Duke University Opportunities in Statistical Design, Analysis, and Modeling Susan Ellenberg, University of Pennsylvania School of Medicine IT Infrastructure, Informatics and Scientific Computing in Regulatory Science Sangtae Kim, Morgridge Institute for Research
Read the entire page →
From page 59...
... America 3:15–3:45 HHS PERSPECTIvE Protecting the Public through Regulatory Science -- A National Priority William Corr, HHS Deputy Secretary 3:45–4:00 SuMMARy AND NEXT STEPS gail Cassell, Eli Lilly and Company 1 Unable to attend the workshop due to weather.
Read the entire page →

Key Terms

  • gail cassell
  • eli lilly
  • drug discovery
  • perspective protecting
  • national priority

  • hhs perspective
  • william corr
  • deputy secretary
  • hhs deputy
  • discovery institute

  • allen roses
  • deane drug
  • steps gail
  • duke university
  • workshop due

  • genomics allen
  • barbara alving
  • predict rare
  • drug safety
  • modeling susan

  • morgridge institute
  • adverse reactions
  • science sangtae
  • national center
  • pennsylvania school

  • paul watkins
  • priority william
  • north carolina
  • scientific computing
  • sangtae kim


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.